NOTE: This video is ONLY available to watch in selected countries and geographies
[geoip-content country=”EU, GB, AR, AU, BA, CO, CR, EC, GT, IN, ID, MK, MX, PE, RU, SA, SG, KR, TW, TR, TH, UY, UA, AT, BE, BG, HR, CY, CZ, DK, EE, FI, FR, DE, GR, HU, IE, IT, LV, LT, LU, MT, NL, PL, PT, RO, SI, SK, ES, SE”]
Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New Zealand) to distil the headline findings from the first-ever results of the IN.PACT AV access clinical study-just after Holden’s presentation at the CIRSE annual meeting (7-11 September, Barcelona, Spain).
The trial compared the IN.PACT drug coated balloon (DCB) to percutaneous transluminal angioplasty (PTA) in patients with de novo or non-stented restenotic arteriovenous (AV) fistula lesions. The study met primary safety and effectiveness endpoints at six months.
Holden tells van den Berg that the “impressive” 82.2% primary patency achieved with DCB use, as compared to 59.5% with plain angioplasty, demonstrates a highly significant difference. He also emphasises that the 56% reduction in reintervention rate achieved with the DCB would “resonate significantly”, particularly for patients, and might pave the way for DCB treatment to become standard of care.
Alexandros Mallios (Paris, France) and Matteo Tozzi (Varese, Italy) shared early reactions on how these data might impact clinical practice and benefit patients.
This video is sponsored by Medtronic.
[/geoip-content]
